CoChat

Fluoxetine: a review on evidence based medicine

Open access
Rossi, Andrea, Barraco, Alessandra, Donda, Pietro · 2004 · Annals of General Hospital Psychiatry
Cited by 132

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BackgroundFluoxetine was the first molecule of a new generation of antidepressants, the Selective Serotonin Re-uptake Inhibitors (SSRIs). It is recurrently the paradigm for the development of any new therapy in the treatment of depression. Many controlled studies and meta-analyses were performed on Fluoxetine, to improve the understanding of its real impact in the psychiatric area. The main objective of this review is to assess the quality and the results reported in the meta-analyses published on Fluoxetine.MethodsPublished articles on Medline, Embase and Cochrane databases reporting meta-analyses were used as data sources for this review.Articles found in the searches were reviewed by 2 independent authors, to assess if these were original meta-analyses. Only data belonging to the most recent and comprehensive meta-analytic studies were included in this review.ResultsData, based on a group of 9087 patients, who were included in 87 different randomized clinical trials, confirms that fluoxetine is safe and effective in the treatment of depression from the first week of therapy. Fluoxetine's main advantage over previously available antidepressants (TCAs) was its favorable safety profile, that reduced the incidence of early drop-outs and improved patient's compliance, associated with a comparable efficacy on depressive symptoms. In these patients, Fluoxetine has proven to be more effective than placebo from the first week of therapy.Fluoxetine has shown to be safe and effective in the elderly population, as well as during pregnancy. Furthermore, it was not associated with an increased risk of suicide in the overall evaluation of controlled clinical trials.The meta-analysis available on the use of Fluoxetine in the treatment of bulimia nervosa shows that the drug is as effective as other agents with fewer patients dropping out of treatment.Fluoxetine has demonstrated to be as effective as chlomipramine in the treatment of Obsessive-Compulsive-Disorder (OCD).ConclusionFluoxetine can be considered a drug successfully used in several diseases for its favorable safety/efficacy ratio. As the response rate of mentally ill patients is strictly related to each patient's personal characteristics, any new drug in this area, will have to be developed under these considerations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2832-3-2

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 40

  1. Wong DT, Bymaster FP, Engleman EA: Minireview: Prozac (Fluoxetine, Lilly 110140), the first selective selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995, 57: 411-441. 10.1016/0024-3205(95)00209-O. · DOI · Paper page
  2. Guze BH, Gitlin M: New antidepressants and the treatment of depression. J Fam Pract. 1994, 38: 49-57.
  3. American Medical Association: Psychopharmacologic drugs. In: Drugs used in mood disorders. Drug evaluation subscription. 1992, Chicago Ill, 1: 32-
  4. Cheer SM, Goa KL: Fluoxetine: A review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001, 61 (1): 81-110. · DOI
  5. Simpson K, Noble S: Fluoxetine: A review of its use in women's health. CNS Drugs. 2000, 14 (4): 301-328. · DOI
  6. Wilde MI, Benfield P: Fluoxetine: A pharmacoeconomic review of its use in depression. PharmacoEconomics. 1998, 13 (5): 543-561. · DOI
  7. Stokes PE, Holtz A: Fluoxetine tenth anniversary update: The progress continues. Clinical Therapeutics. 1997, 19 (5): 1135-1150. 10.1016/S0149-2918(97)80066-5. · DOI
  8. Scott LV: Fluoxetine: A review of its pharmacology and clinical applications. Journal of Serotonin Research. 1997, 3 (4): 173-191.
  9. Bakker A, Van Balkom AJLM, Spinhoven P: SSRIs vs. TCAs in the treatment of panic disorder: A meta-analysis. Acta Psychiatrica Scandinavica. 2002, 106 (3): 163-167. 10.1034/j.1600-0447.2002.02255.x. · DOI · Paper page
  10. Khan A, Leventhal RM, Khan S, Brown WA: Suicide risk in patients with anxiety disorders: A meta-analysis of the FDA database. Journal of Affective Disorders. 2002, 68 (2-3): 183-190. 10.1016/S0165-0327(01)00354-8. · DOI · Paper page
  11. Furukawa TA, Streiner DL, Young LT: Is antidepressant–benzodiazepine combination therapy clinically more useful? A meta-analytic study. Journal of Affective Disorders. 2001, 65 (2): 173-177. 10.1016/S0165-0327(00)00254-8. · DOI
  12. De Lima MS, Hotoph M, Wessely S: The efficacy of drug treatments for dysthymia: A systematic review and meta-analysis. Psychological Medicine. 1999, 29 (6): 1273-1289. 10.1017/S0033291799001324. · DOI · Paper page
  13. Rossy LA, Buckelew SP, Dorr N, Hagglund KJ, Thayer JF, McIntosh MJ, Hewett JE, Johnson JC: A meta-analysis of fibromyalgia treatment interventions. Annals of Behavioral Medicine. 1999, 21 (2): 180-191. · DOI · Paper page
  14. Anderson IM: SSRIS versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability. Depression and Anxiety. 1998, 7 (SUPPL 1): 11-17. 10.1002/(SICI)1520-6394(1998)7:1+<11::AID-DA4>3.3.CO;2-O. · DOI · Paper page
  15. Michael KD, Crowley SL: How effective are treatments for child and adolescent depression? A meta-analytic review. Clinical Psychology Review. 2002, 22 (2): 247-269. 10.1016/S0272-7358(01)00089-7. · DOI · Paper page
  16. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. Journal of Nervous and Mental Disease. 1994, 182 (10): 547-551. · DOI · Paper page
  17. Burrows GD, Norman TR: Suicide, violent behaviour and fluoxetine: Meta-analysis of clinical trials shows that fluoxetine does not cause or increase suicidal behaviour or violent acts. Medical Journal of Australia. 1994, 161 (7): 404-405. · doi:10.5694/j.1326-5377.1994.tb127518.x
  18. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN: Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991, 303 (6804): 685-92. · DOI · Paper page
  19. Falsetti AE: Fluoxetine–induced suicidal ideation: An examination of the medical literature, case law, and the legal liability of drug manufacturers. Food and Drug Law J. 2002, 57: 247-267.
  20. Jarema M: The use of meta–analysis in the evaluation of antidepressive effects of fluoxetine. Psychiatria Polska. 1996, 30 (4): 569-581.
  21. Carr Roxane R, Ensom Mary HH: Fluoxetine in the treatment of premenstrual dysphoric disorder. The annals of pharmacotherapy. 2002, 36 (4): 713-7. · doi:10.1345/aph.1a265
  22. Anderson IM: Meta–analytical studies on new antidepressants. British Medical Bulletin. 2001, 57: 161-178. 10.1093/bmb/57.1.161. · DOI · Paper page
  23. Jenike MA, Bear L, Greist JH: Clomipramine versus fluoxetine in obsessive-compulsive disorder: A retrospective comparison of side effects and efficacy. Journal of Clinical Psychopharmacology. 1990, 10: 122-124. · DOI · Paper page
  24. Myers JK, Weissman MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD, Kramer M, et al: Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Archives of General Psychiatry. 1984, 41 (10): 959-67. · DOI · Paper page
  25. Borson S, Barnes RA, Kukull WA, Okimoto JT, Veith RC, Inui TS, Carter W, Raskind MA: Symptomatic depression in elderly medical outpatients. I. Prevalence, demography, and health service utilization. Journal of the American Geriatrics Society. 1986, 34 (5): 341-7. · DOI · Paper page
  26. Blazer D, Hughes DC, George LK: The epidemiology of depression in an elderly community population. Gerontologist. 1987, 27 (3): 281-7. · DOI · Paper page
  27. Alexopoulos GS, Young RC, Meyers BS, Abrams RC, Shamoian CA: Late-onset depression. Psychiatric Clinics of North America. 1988, 11 (1): 101-15. · DOI
  28. Girling DM, Barkley C, Paykel ES, Gehlhaar E, Brayne C, Gill C, Mathewson D, Huppert FA: The prevalence of depression in a cohort of the very elderly. Journal of Affective Disorders. 1995, 34 (4): 319-29. 10.1016/0165-0327(95)00030-Q. · DOI
  29. Markush RE, Schwab JJ, Farris MA, et al: Mortality and community mental health. Arch Gen Psychiatry. 1977, 34: 1393-1401. · doi:10.1001/archpsyc.1977.01770240019001
  30. Enzell K: Mortality among persons with depressive symptoms and among responders and non-responders in a health check-up. An investigation of persons born in 1905 and followed up from age 66 to 75. Acta Psychiatrica Scandinavica. 1984, 69 (2): 89-102. · DOI
  31. Bruce ML, Seeman TE, Merrill SS, Blazer DG: The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. American Journal of Public Health. 1994, 84 (11): 1796-9. · DOI · Paper page
  32. Addis A, Koren G: Safety of fluoxetine during the first trimester of pregnancy: A meta–analytical review of epidemiological studies. Psychological Medicine. 2000, 30 (1): 89-94. 10.1017/S0033291799001270. · DOI · Paper page
  33. Bacaltchuk J, Hay P: Antidepressants versus placebo for people with bulimia nervosa. The Cochrane Library. 2003, 1 · DOI · Paper page
  34. Beasley CM, Koke SC, Nilsson ME, Gonzales JS: Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clinical Therapeutics. 2000, 22 (11): 1319-1330. 10.1016/S0149-2918(00)83028-3. · DOI
  35. Beasley CM, Nilsson ME, Koke SC, Gonzales JS: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20-mg/day dose. Journal of Clinical Psychiatry. 2000, 61 (10): 722-728. · DOI · Paper page
  36. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN: Fluoxetine and suicide: a meta–analysis of controlled trials of treatment for depression. International Clinical Sychopharmacology. 1992, 6 (SUPPL. 6): 35-57. · doi:10.1097/00004850-199206006-00006
  37. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD: Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry. 2000, 176: 421-428. 10.1192/bjp.176.5.421. · DOI · Paper page
  38. Cox BJ, Swinson RP, Morrison B, Lee PS: Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive–compulsive disorder: A meta–analysis. Journal of Behavior Therapy and Experimental Psychiatry. 1993, 24 (2): 149-153. 10.1016/0005-7916(93)90043-V. · DOI · Paper page
  39. Hoog S, Tepner R, Nilsson ME, Romano S, Kennedy JS: Changes in anxiety, agitation, and insomnia during treatment of depression for patients age 55 years and older: Analysis from fluoxetine double-blind, placebo-controlled trials. International Journal of Geriatric Psychopharmacology. 1999, 2 (1): 33-39.
  40. Tollefson GD, Holman SL: How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. International Clinical Psychopharmacology. 1994, Winter 9 (4): 245-50. · DOI · Paper page

Cited by

Metadata

Authors
Rossi, A., Barraco, A., & Donda, P.
Venue
Annals of General Hospital Psychiatry
Published
2004-02-12
Volume
3
Issue
1
Pages
2-2
ISSN
1475-2832 (ISSN-L)
OpenAlex
W2100309178
Cited by
132
References
3
FWCI
3.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.